Real-world effectiveness of mepolizumab for the treatment of severe asthma with overlapping eosinophilic comorbidities Running head: Mepolizumab in eosinophilic comorbidities

Background: Severe eosinophilic asthma frequently coexists with eosinophilic disorders involving other organs. Although mepolizumab is effective for severe eosinophilic asthma, real-world data on patients with overlapping eosinophilic comorbidities remain limited. Methods: This retrospective, single-center study included 25 patients with severe eosinophilic asthma treated with mepolizumab. Asthma Control Test (ACT) scores, forced expiratory volume in 1 s (FEV1), peripheral blood eosinophil (PBE) counts, and oral corticosteroid (OCS) doses were evaluated at baseline and week 16. Treatment response was assessed at week 16 using the Global Evaluation of Treatment Effectiveness (GETE), and subsequent treatment course was examined for up to 12 months. Results: Comorbid eosinophilic diseases included eosinophilic granulomatosis with polyangiitis, chronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, and eosinophilic chronic rhinosinusitis/eosinophilic otitis media. At week 16, median PBE counts decreased from 745 to 44/µL and OCS doses from 7.5 to 4.0 mg/day. Median ACT scores increased from 18 to 23 and FEV1 from 1.89 to 2.08 L. Nineteen patients (76%) had an Excellent or Good GETE response; 18 continued mepolizumab through Month 12, with follow-up unavailable for one. Of the six patients with a Moderate or Poor response, four switched biologics, one discontinued biologic treatment, and one continued mepolizumab with delayed improvement. Conclusions: Mepolizumab was associated with improved asthma control, reduced eosinophil counts, and lower OCS requirements in patients with severe asthma and overlapping eosinophilic comorbidities. Assessment at week 16 also provided a practical decision point for subsequent continuation or modification of biologic therapy.

Authors

Publication Details

Journal
International Archives of Allergy and Immunology
Published
2026-11-21
DOI
https://doi.org/10.1159/iaa/adfag049
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world effectiveness of mepolizumab for the treatment of severe asthma with overlapping eosinophilic comorbidities Running head: Mepolizumab in eosinophilic comorbidities

Shinya Yokoe, Tomoko Iriyama, Masafumi Yamaguchi, Yoko Tsunoda et al.
International Archives of Allergy and Immunology
Asthma and respiratory diseases
article

Real-world effectiveness of mepolizumab for the treatment of severe asthma with overlapping eosinophilic comorbidities Running head: Mepolizumab in eosinophilic comorbidities

Shinya Yokoe, Tomoko Iriyama, Masafumi Yamaguchi, Yoko Tsunoda, Yasutaka Nakano, Hiroaki Nakagawa, Akio Yamazaki, Daisuke Kinose, Makoto Osawa, Emiko Ogawa
article en

Abstract

Background: Severe eosinophilic asthma frequently coexists with eosinophilic disorders involving other organs. Although mepolizumab is effective for severe eosinophilic asthma, real-world data on patients with overlapping eosinophilic comorbidities remain limited. Methods: This retrospective, single-center study included 25 patients with severe eosinophilic asthma treated with mepolizumab. Asthma Control Test (ACT) scores, forced expiratory volume in 1 s (FEV1), peripheral blood eosinophil (PBE) counts, and oral corticosteroid (OCS) doses were evaluated at baseline and week 16. Treatment response was assessed at week 16 using the Global Evaluation of Treatment Effectiveness (GETE), and subsequent treatment course was examined for up to 12 months. Results: Comorbid eosinophilic diseases included eosinophilic granulomatosis with polyangiitis, chronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, and eosinophilic chronic rhinosinusitis/eosinophilic otitis media. At week 16, median PBE counts decreased from 745 to 44/µL and OCS doses from 7.5 to 4.0 mg/day. Median ACT scores increased from 18 to 23 and FEV1 from 1.89 to 2.08 L. Nineteen patients (76%) had an Excellent or Good GETE response; 18 continued mepolizumab through Month 12, with follow-up unavailable for one. Of the six patients with a Moderate or Poor response, four switched biologics, one discontinued biologic treatment, and one continued mepolizumab with delayed improvement. Conclusions: Mepolizumab was associated with improved asthma control, reduced eosinophil counts, and lower OCS requirements in patients with severe asthma and overlapping eosinophilic comorbidities. Assessment at week 16 also provided a practical decision point for subsequent continuation or modification of biologic therapy.

International Archives of Allergy and Immunology
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon